Cargando…
Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials
BACKGROUND: Individual randomized trials are not powered to assess the relationship between use of sodium–glucose transporter 2 inhibitors and risk of stroke. We sought to explore this issue by a meta-analysis incorporating relevant trials including several latest trials. METHODS: Cardiovascular out...
Autores principales: | Zhao, Li-Min, Huang, Jia-Nan, Qiu, Mei, Ding, Liang-Liang, Zhan, Ze-Lin, Ning, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483857/ https://www.ncbi.nlm.nih.gov/pubmed/34596148 http://dx.doi.org/10.1097/MD.0000000000027362 |
Ejemplares similares
-
Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis
por: Chang, Rong, et al.
Publicado: (2021) -
Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis
por: Qiu, Mei, et al.
Publicado: (2021) -
Meta-regression analysis of the efficacy of alendronate for prevention of glucocorticoid-induced fractures
por: Qiu, Mei, et al.
Publicado: (2020) -
Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis
por: Qiu, Mei, et al.
Publicado: (2020) -
A randomized controlled trial protocol of the cardiovascular safety and efficacy of liraglutide in the treatment of type 2 diabetes
por: Liang, Ying, et al.
Publicado: (2021)